Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:32:43.810Z.
Calculation as of: 2026-10-06T16:32:43.810Z.
Quote observation: 2026-10-06T16:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
TuHURA Biosciences, Inc.
Market Cap
$121.95M
Operating Cash Flow Yield
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD |
|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $121.95M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $122.26M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.34M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.05M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.82M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.65M | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
